CTI: Pacritinib Is Sole Product Candidate in Active Development
CTI: Pacritinib Is Sole Product Candidate in Active Development
*DJ CTI BioPharma Corp. Looks to Raise $50.7 Million via Stock Offer
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:53 ET (03:53 GMT)
*DJ CTI Offering 14,260,800 Shares of Common Stock, 600 Shares of Series X(1) Preferred Stock
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:54 ET (03:54 GMT)
*DJ CTI Common Stock Priced at $2.50 Each, Preferred Stock Priced at $25,000
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:55 ET (03:55 GMT)
*DJ CTI: Each Preferred Share Will Be Convertible Into 10,000 Common Shares
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:55 ET (03:55 GMT)
*DJ CTI Has Granted Underwriters Option for Additional 2,139,120 Common Shares
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:56 ET (03:56 GMT)
*DJ CTI Offering Is Expected to Close on or About April 6
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:56 ET (03:56 GMT)
*DJ CTI Intends to Use Proceeds for Commercialization Activities for Pacritinib
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:57 ET (03:57 GMT)
*DJ CTI: Pacritinib Is Sole Product Candidate in Active Development
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:58 ET (03:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
*DJ CTI BioPharma Corp. Looks to Raise $50.7 Million via Stock Offer
*DJ CTI BioPharma Corp.希望通过股票发售筹集5070万美元
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:53 ET (03:53 GMT)
2021年3月31日美国东部时间23：53(格林尼治标准时间03：53)
*DJ CTI Offering 14,260,800 Shares of Common Stock, 600 Shares of Series X(1) Preferred Stock
*DJ CTI发售14,260,800股普通股，600股X(1)系列优先股
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:54 ET (03:54 GMT)
2021年3月31日美国东部时间23：54(格林尼治标准时间03：54)
*DJ CTI Common Stock Priced at $2.50 Each, Preferred Stock Priced at $25,000
*DJ CTI普通股定价为每股2.50美元，优先股定价为25,000美元
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:55 ET (03:55 GMT)
2021年3月31日美国东部时间23：55(格林尼治标准时间03：55)
*DJ CTI: Each Preferred Share Will Be Convertible Into 10,000 Common Shares
*DJ CTI：每股优先股将可转换为10,000股普通股
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:55 ET (03:55 GMT)
2021年3月31日美国东部时间23：55(格林尼治标准时间03：55)
*DJ CTI Has Granted Underwriters Option for Additional 2,139,120 Common Shares
*DJ CTI已授予承销商额外2,139,120股普通股的选择权
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:56 ET (03:56 GMT)
2021年3月31日美国东部时间23：56(格林尼治标准时间03：56)
*DJ CTI Offering Is Expected to Close on or About April 6
*DJ CTI产品预计将于4月6日左右结束
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:56 ET (03:56 GMT)
2021年3月31日美国东部时间23：56(格林尼治标准时间03：56)
*DJ CTI Intends to Use Proceeds for Commercialization Activities for Pacritinib
*DJ CTI打算将收益用于Pacritinib的商业化活动
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:57 ET (03:57 GMT)
2021年3月31日美国东部时间23：57(格林尼治标准时间03：57)
*DJ CTI: Pacritinib Is Sole Product Candidate in Active Development
*DJ CTI：帕利替尼是积极开发的唯一候选产品
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 31, 2021 23:58 ET (03:58 GMT)
2021年3月31日美国东部时间23：58(格林尼治标准时间03：58)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧